louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02775396: Effects of Wearing Progressive Addition Lens on Working Distance and Refractive Status in Adult Computer Users
Official title: Effects of Wearing a New Progressive Addition Lens on Working Distance and Refractive Status in Adult Chinese Computer Users
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Video Game Play Using Handheld Computer
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
Collaborators: name: Carl Zeiss
First posted: 2016-05-17
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: With the increasing reliance on tablet computers and smartphones in daily life, it is important to determine whether and how the prolonged usage of these handheld digital devices influences the working habits and refractive status. This study aimed to determine the effects of wearing conventional single-vision lenses vs. new progressive addition lenses on the working distance and refractive status while playing interactive video game in Chinese pre-presbyopic adult computer users.

Detailed description: Chinese adult computer users were recruited from two age cohorts. They were prescribed, in random order, with conventional single-vision lenses and progressive addition lenses designed for handheld digital display devices (iPad). Basic ocular parameters were measured through a comprehensive eye examination at the baseline visit. Working distance and refractive shift were measured immediately after delivering the lenses and after one month of lens wear. Working distance were recorded with an automatic ultrasound sensor while the participants were playing a 30-minute video game. Refractive-error shift before and after playing the video game were measured with an open-field autorefractor in both eyes and averaged.

Eligibility criteria: Inclusion Criteria:

* Hong Kong Chinese
* Computer users (computer usage \>2hours/day)
* Spherical-equivalent refractive errors between plano and -9.00D and cylindrical power ≤2.50D

Exclusion Criteria:

* Anyone with visual acuity worse than 0 logMAR, anisometropia more than 2.00D, abnormal accommodative function, wearing rigid contact lens, and a history of ocular surgery and pathology

Primary outcomes:
measure: Change in near working distance measured by an automatic ultrasound sensor
timeFrame: Change in near working distance after one month of lens wear
measure: Change in refractive status measured by an automatic refractometer
timeFrame: Change in refractive status shift after one month of lens wear
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The Hong Kong Polytechnic University
name: Chea-su Kee, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kee CS, Leung TW, Kan KH, Lam CH. Effects of Progressive Addition Lens Wear on Digital Work in Pre-presbyopes. Optom Vis Sci. 2018 May;95(5):457-467. doi: 10.1097/OPX.0000000000001211.
Clinical trial NCT02047396: Ventricular Remodeling and Heart Failure After Myocardial Infarction: a Community Study
Official title: Ventricular Remodeling and Heart Failure After Myocardial Infarction: a Community Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Heart Failure
Myocardial Infarction
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2014-01-28
Enrollment: 1599
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects in the 7 County area who are admitted to the Mayo Clinic Hospitals in Rochester, Minnesota who have their first myocardial infarction and are willing to have blood drawn and return for an echocardiogram in 3 months.

Brief summary: To comprehensively characterize Left Ventricular (LV) remodeling after Myocardial Infarction (MI) in the community, study the association between patterns of remodeling and biological pathways and examine the association between the predictors of remodeling and heart failure after Myocardial Infarction.


Eligibility criteria: Inclusion Criteria:

1. Hospitalized patients with a clinical diagnosis of Myocardial Infarction.
2. Residents of Olmsted, Dodge, Goodhue, Wabasha, Winona, Fillmore and Mower Counties.
3. Able to provide informed consent.

Exclusion Criteria:

1. Previous clinical diagnosis of Myocardial Infarction
2. Previous diagnosis of Heart Failure and/or Cardiomyopathy
3. Diagnosis of Apical Ballooning Syndrome
4. Planned Coronary Artery Bypass Graft (CABG) during index hospitalization
5. Unable to provide informed consent

Primary outcomes:
measure: Heart Failure
timeFrame: 5 years
Secondary outcomes:
measure: Death
timeFrame: 5 years
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Suzette Bielinski, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05697796: Comparison of Post-operative Symptoms After Two Surgeries for Patients With Pelvic Organ Prolapse
Official title: Comparison of Post-operative Lower Urinary Tract Symptoms After Sacrospinous Ligament Fixation or Extraperitoneal High Uterosacral Ligament Suspension for Patients With Pelvic Organ Prolapse
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pelvic Organ Prolapse
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2023-01-26
Enrollment: 2
Sex: FEMALE
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients had pelvic organ prolapse receiving two specific surgical methods

Brief summary: Collect and review the patients who underwent surgical treatment due to pelvic floor organ prolapse from 2020 to 2021, make statistics on their postoperative questionnaire data, and evaluate the clinical effects of different surgical methods


Eligibility criteria: Inclusion Criteria:

* Age ≥ 30 years;

  * Because pelvic organ prolapse in our hospital, we performed extraperitoneal high sacral ligament suspension or sacrospinal ligament fixation; ③ Those who have no surgical contraindication and can tolerate surgery and anesthesia.

Exclusion Criteria:

* Those who cannot tolerate surgery and anesthesia; ② Patients receiving other tip suspension techniques.

Primary outcomes:
measure: changes in POP-Q score at different time nodes
timeFrame: pre-operation and post-operation(1month, 3 months and 6 months )
Secondary outcomes:
measure: UDI-6 scores at different time nodes
timeFrame: pre-operation and post-operation(1month, 3 months and 6 months )
measure: PFDI-20 scores at different time nodes
timeFrame: pre-operation and post-operation(1month, 3 months and 6 months )
measure: OABss scores at different time nodes
timeFrame: pre-operation and post-operation(1month, 3 months and 6 months )
Other outcomes:
Locations:
city: Beijing
country: China
facility: The Peking University People's Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT00769496: BAY 77-1931 Long-term Extension From Phase II Study
Official title: A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hyperphosphatemia
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2008-10-09
Enrollment: 145
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis


Eligibility criteria: Inclusion Criteria:

* Undergoing hemodialysis 3 times per week for chronic renal failure for the previous 3 consecutive months at least

Exclusion Criteria:

* Pre-dialysis serum phosphate levels of 10.0mg/dL during the washout period

Primary outcomes:
measure: Changes in pre-dialysis serum phosphate levels
timeFrame: Every 4 weeks
Secondary outcomes:
measure: Achievement rate of the target predialysis serum phosphate levels (3.5 mg/dL and 5.5 mg/dL)
timeFrame: Every 4 weeks
measure: Changes in corrected serum calcium level
timeFrame: Every 4 weeks
measure: Changes in the product of serum calcium and phosphate
timeFrame: Every 4 weeks
measure: Changes in serum intact-PHT levels
timeFrame: Every 4 weeks
measure: Changes in bone metabolism markers
timeFrame: Every 4 weeks
Other outcomes:
Locations:
city: Toyohashi
country: Japan
state: Aichi
city: Yatomi
country: Japan
state: Aichi
city: Kashiwa
country: Japan
state: Chiba
city: Narita
country: Japan
state: Chiba
city: Sakura
country: Japan
state: Chiba
city: Asahikawa
country: Japan
state: Hokkaido
city: Suita
country: Japan
state: Osaka
city: Chiba
country: Japan
city: Hiroshima
country: Japan
city: Kochi
country: Japan
city: Kochi
country: Japan
city: Kochi
country: Japan
city: Okayama
country: Japan
city: Tokushima
country: Japan
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00037596: Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
Official title: A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Myeloid Leukemia
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2002-05-20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.


Eligibility criteria: Inclusion Criteria:

* Morphologic diagnosis of AML from bone marrow aspirate and biopsy
* Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33+, based on local laboratory criteria
* Age 18 years or older for relapsed or refractory patients for Phase I of this study

Exclusion Criteria:

* Patients with de novo AML of the M3 subtype
* AML following an antecedent hematologic disorder (myelodysplasia or myeloproliferation) of \> 2 months duration
* AML secondary to exposure to chemotherapy or radiation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor, MD
role: STUDY_DIRECTOR
References:
citation: Hibma J, Knight B. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia. Clin Pharmacokinet. 2019 Mar;58(3):335-347. doi: 10.1007/s40262-018-0699-5.
Clinical trial NCT01866696: Computer Assisted Implant Surgery and Immediate Loading
Official title: Computer Assisted Implant Surgery and Immediate Loading With Full-arch Screw Retained Prosthesis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Edentulous Jaws
Keywords: Computer assisted implant surgery,
Immediate loading,
CAD/CAM
Lead sponsor: Università degli Studi di Sassari
Sponsor class: OTHER
First posted: 2013-05-31
Enrollment: 20
Sex: ALL
Minimum age (years): 39
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Purpose: The aim of this study was to analyze the clinical and radiographic outcomes of 23 edentulous jaws treated with 3D software planning, guided surgery, immediate loading and restored with Cad-Cam Zirconia and titanium full arch frameworks.

Material \& methods: This study was designed as a prospective clinical trial. Twenty patients have been consecutively rehabilitated with an immediately loaded implant supported fixed full prosthesis. A total of 120 fixtures supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. All the implants were inserted with an insertion torque of 35/45 Ncm. 117 out of 120 implants were immediately loaded the other 3 were delayed loaded.

Outcome measures were implants survival, radiographic marginal bone-levels and bone remodeling, soft tissue parameters and complications.


Eligibility criteria: Inclusion criteria were:

-edentulous patients or patients with hopeless teeth in need to be restored with full arches prosthesis

Exclusion criteria were:

* presence of systemic diseases (i.e. haematologic disease, uncontrolled diabetes, serious coagulopathies and diseases of the immune system)
* irradiation to the head or neck region within 12 months before surgery
* presence severe bruxism or clenching habits
* pregnancy
* poor oral hygiene
* poor motivation to return for scheduled follow-up visit

Primary outcomes:
measure: implants survival
timeFrame: 0-30 months
Secondary outcomes:
measure: peri-implant bone
timeFrame: 12-30 months
Other outcomes:
measure: peri-implant mucosal response
timeFrame: 12-30 months
measure: prosthetic success
timeFrame: 0-30 months
measure: biological and prosthetic complication
timeFrame: 12-30 months
Locations:
city: Sassari
country: Italy
facility: University of Sassari
state: SS
Study officials:
affiliation: Università degli Studi di Sassari
name: Silvio M Meloni, DDS
role: STUDY_DIRECTOR
References:
citation: Meloni SM, De Riu G, Pisano M, Lolli FM, Deledda A, Campus G, Tullio A. Implant Restoration of Edentulous Jaws with 3D Software Planning, Guided Surgery, Immediate Loading, and CAD-CAM Full Arch Frameworks. Int J Dent. 2013;2013:683423. doi: 10.1155/2013/683423. Epub 2013 Jul 29.
Clinical trial NCT02588196: The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Tuberculous Meningitis
Lead sponsor: Hebei Medical University
Sponsor class: OTHER
First posted: 2015-10-27
Enrollment: 200
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study aimed to evaluate the relationships between the gene polymorphisms of leukotriene A4 hydrolase(LTA4H) and Dexamethasone treatment for tuberculous meningitis in Chinese patients.


Eligibility criteria: Inclusion Criteria:

patients were eligible to enter the study if they met the diagnositic criteria for possible, probable or definite Tuberculosis meningitis(TBM).

Exclusion Criteria:

Patients were excluded if they were infected with HIV, diagnosed as carcinomatous meningitis, viral meningitis, purulent meningitis, cryptococcus meningitis.

Primary outcomes:
measure: MRI
timeFrame: 6 month
measure: changes of cerebrospinal fluid
timeFrame: 1 year
measure: changes of clinical symptoms
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06126796: Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Official title: A Randomized Cross-Over Study to Evaluate Patient Preference and Satisfaction With Urine-based Molecular Testing Versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Non-muscle Invasive Bladder Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male or female adult patients who are undergoing cystoscopic surveillance for NMIBC after at least 9 months of recurrence-free survival.

Brief summary: The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.


Eligibility criteria: Inclusion Criteria:

* Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence.
* Able to provide urine for testing and comply with study protocol.
* Have an email address and be willing to complete surveys online.

Exclusion Criteria:

* History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma)
* Patients with predominant (\>50%) variant histology
* Patients with a history of upper tract and/or urethral cancer
* Women who are pregnant

Primary outcomes:
measure: Preference for CxBladder Monitor compared to cystoscopy
timeFrame: Up to 6 months
Secondary outcomes:
measure: Patient satisfaction
timeFrame: Up to 6 months
measure: Change in symptoms and function - EORTC NMIBC-24
timeFrame: Up to 6 months
measure: Fear of Cancer Recurrence Inventory- Short Form (FCRI-SF)
timeFrame: Up to 6 months
measure: Financial costs
timeFrame: Up to 6 months
measure: Error rate identifying recurrent nonmuscle invasive bladder cancer (NMIBC)
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Mark D. Tyson, M.D., M.P.H.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05782296: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate
Official title: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate: TrueLabor™, A New External Monitoring Device: Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor
Uterine Contractions
Obstetric Complication
Keywords: Fetal Heart Rate
Uterine Activity
TrueLabor
OB Tools
Non invasive monitoring
Lead sponsor: OB-Tools Ltd.
Sponsor class: INDUSTRY
First posted: 2023-03-23
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women (age\>18 y/o) in active labor following rupture of membranes and placement of an IUPC and/or FSE.

Brief summary: A clinical study designed to validate the safety and performance of the TrueLabor™ device in monitoring labor vs. current standard of care.


Eligibility criteria: Inclusion Criteria:

* Women who are on \>=37w0d of gestation
* Maternal age \> 18 years old
* Singleton pregnancy
* Cephalic presentation
* Patient requiring internal monitoring for obstetric indications
* Informed consent

Exclusion Criteria:

* Major fetal anomalies
* Patients with implanted electronic devices of any kind
* Patients using exterior electronic devices of any kind during the procedure
* Patients with irritated skin or open wound on the abdominal wall

Primary outcomes:
measure: Safety, comparative performance, and reliability of the TrueLabor™ system for Fetal Heart Rate
timeFrame: Through labor, until delivery
measure: Safety, comparative performance, and reliability of the TrueLabor™ system for Uterine Activity
timeFrame: Through labor, until delivery
Secondary outcomes:
measure: Effect of BMI (weight in Kg, height in meters will be combined to report BMI in kg/m2)
timeFrame: Through labor, until delivery
Other outcomes:
Locations:
city: Hoffman Estates
country: United States
facility: Ascension Illinois Saint Alexius Residency Program in Obstetrics and Gynecology
state: Illinois
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT03048396: Acceptance of Uterus Transplantation
Official title: Transplantation of an Uterus for Treatment of an Absolute Uterine Infertility
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Resolve Infertility
Lead sponsor: University Women's Hospital Tübingen
Sponsor class: OTHER
First posted: 2017-02-09
Enrollment: 10
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Transplantation of an uterus

Detailed description: Uterus transplantation will be performed from live donors to patients with absolute uterine factor infertility. Organ procurement from the donor will be performed by laparotomy. Transplantation will also be performed by laparotomy. Embryo transfer will be done 10-12 months after transplantation. After birth of 1-3 children the uterus will be removed by hysterectomy.

Eligibility criteria: Inclusion Criteria:

* age below 40 years
* absolute uterine factor infertility
* BMI \< 30

Exclusion Criteria:

* systemic disease
* psychiatric disease

Primary outcomes:
measure: Number of patients who are interested in an uterus transplantation
timeFrame: 3 years
measure: Number of patients from these who do have a potential donor
timeFrame: 3 years
measure: Number of patients from these who do have a medical indication for an uterus transplantation
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Research Institute for Women's Health
name: Sara Brucker, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brucker SY, Brannstrom M, Taran FA, Nadalin S, Konigsrainer A, Rall K, Scholler D, Henes M, Bosmuller H, Fend F, Nikolaou K, Notohamiprodjo M, Rosenberger P, Grasshoff C, Heim E, Kramer B, Reisenauer C, Hoopmann M, Kagan KO, Dahm-Kahler P, Kvarnstrom N, Wallwiener D. Selecting living donors for uterus transplantation: lessons learned from two transplantations resulting in menstrual functionality and another attempt, aborted after organ retrieval. Arch Gynecol Obstet. 2018 Mar;297(3):675-684. doi: 10.1007/s00404-017-4626-z. Epub 2017 Dec 21.